A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease

Neurobiology of Disease

Volumn 8, Issue 5, 2001, Pages 890-899

  Refolo, L M ^a   Pappolla, M A ^b   LaFrancois, J ^a   Malester, B ^a   Schmidt, S D ^a   Thomas Bryant, T ^b   Tint, G S ^c   Wang, R ^d   Mercken, M ^e   Petanceska, S S ^a   Duff, K E ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e Belgium   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [1 (4 CHLOROCINNAMYL) 4 PIPERAZINYL]ETHYL]BENZOIC ACID; AMYLOID BETA PROTEIN; ANTILIPEMIC AGENT;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0035160066     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2001.0422     Document Type: Article

References (50)

1. Inhibition of cholesterol biosynthesis by BM15.766
2. Lipid binding to amyloid β-peptide aggregates: Preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids
3. 2 techniques in vivo and in vitro
4. Cholesterol homeostasis in the human brain: Turnover of 24S-hydoxycholesterol and evidence for a cerebral origin of most oxysterol in the circulation
5. Stains effective anti-atherosclerotic therapy
6. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein
7. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface
8. A new function for LDL receptor: Transcytosis of LDL across the blood brain barrier
9. Basolateral secretion of amyloid precursor protein in Mardin-Darby canine kidney cells is distributed by alterations of intracellular pH and by introducing a mutation associated with familial Alzheimer's disease
10. Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1
11. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo
12. The role of cholesterol in the biosynthesis of beta-amyloid
13. Neurohormonal signaling pathways and the regulation of Alzheimer β-amyloid precursor metabolism
14. Dietary links to Alzheimer's disease: 1999 update
15. Is there a connection between the concentration of cholesterol circulating in the plasma and the rate of neuritic plaque formation in Alzheimer's disease?
16. Amyloid, the presenilins and Alzheimer's disease
17. Acclerated Alzheimer'stype phenotype in transgenic mice carrying both mutant amyloid precursor and presenilin 1 transgenes
18. Modulation of beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol
19. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice
20. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution
21. Aβ peptide immunization reduces behavioural impairment and β-amyloid plaques in a model of Alzheimer's disease
22. Genetic influences on age related changes in total cholesterol, low density lipoprotein cholesterol, triglyceride levels: Longitudinal apolipoprotein E genotype effects
23. Interactions of apolipoprotein E genotype, total cholesterol level, age, sex, in the prediction of Alzheimer's disease: A case-control study
24. Statins and the risk of dementia
25. Dietary fat intake and the risk of incident dementia in the Rotterdam study
26. Effect of liposomes containing cholesterol on adenylate cyclase activity of cultured mammalian fibroblasts
27. Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein
28. Cholesterol biosynthesis inhibited by BM15.766 induces holoprosencephaly in the rat
29. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives
30. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes
31. Modulation of metarhodopsin formation by cholesterol-induced ordering of bilayer lipids
32. Cholesterol-dependent generation of a unique amyloid beta-protein from apically missorted amyloid precursor protein in MDCK cells
33. Apolipoprotein E in the brain and its role in Alzheimer's disease
34. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model
35. Amyloid and lipids in the pathology of Alzheimers disease
36. Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid β-protein
37. ApolipoproteinE and Alzheimer's disease: An update on genetic and functional analyses
38. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons
39. Induction of Alzhemier's-like beta-amyloid immunoreactivity in brains of rabbits with dietary cholesterol
40. Link between heart disease, cholesterol, and Alzheimer's disease: A review
41. Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms
42. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
43. Age-related Aβ deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and β-amyloid precursor protein is not associated with global neuronal loss
44. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
45. The profile of soluble amyloid beta protein in cultured cell media: Detection and quantification of amyloid beta protein and variants by immunoprecipitation-mass spectrometry
46. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid
47. Decreased prevelence of Alzheimer's disease associated with 3-hydroxy3-methylglutaryl coenzyme A reductase inhibitors
48. Recent advances in brain cholesterol dynamics: Transport, domains and Alzheimer's disease
49. Relationship between abnormal cholesterol synthesis and retarded learning in rats
50. Modulation of membrane function by cholesterol